Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oralgen Grass Pollen in Allergic Rhinoconjunctivitis
NCT00812799Phase 3Unknown
- Sponsor
- Artu Biologicals
- Start
- Dec 2008
- Primary completion
- Aug 2011
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines
- Countries
- 6
01
Overview
A Phase 3 trial of Oralgen Grass Pollen in allergic rhinoconjunctivitis (ARC), sponsored by Artu Biologicals. Status: unknown.
02
Drugs
Oralgen Grass Pollen
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00812799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00812799.